On Nov 07, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $91 to $120.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $81 to $106.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $120.
Piper Sandler analyst Biren Amin maintains with a buy rating, and adjusts the target price from $70 to $91.
Truist Financial analyst Asthika Goonewardene maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The analyst is enhancing their outlook on the potential success of anito-cel after the preliminary results from the iMMagine-1 Phase 2 trial in patients with relapsed/refractory multiple myeloma (rrMM). There is perceived to be a substantial opportunity for market share for anito-cel, initially amongst patients who have received multiple prior lines of therapy and potentially, in the future, in those who are earlier in their treatment journey, should the existing clinical profile remain consistent.
Abstracts from a recent medical conference that presented initial Phase 2 data and additional Phase 1 follow-up information have reaffirmed a pivotal-stage therapy's competitive position and regulatory prospects in the treatment of multiple myeloma. Despite a downturn in the share price, this is perceived as a reaction to recent news following a significant run-up due to abstract anticipation. It is now anticipated that the therapy will achieve a more robust peak market share and has increased chances of success.
The firm indicated a growing positive stance based on updated clinical data. This view was reinforced by the published ASH abstracts, which included initial data from the registrational IMMagine-1 study.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
